Patients with type 2 diabetes have an increased risk of developing acute pancreatitis 65, a rare and potentially serious clinical event that has been observed with GLP-1 RA treatment in liraglutide QD clinical trials 66 and through post-marketing surveillance of marketed exenatide BID 33,67. Here, GLP1R is linked to type 2 diabetes mellitus.